TScan Therapeutics Inc (TCRX)

[jondoeuk]

In that trial (US NCI, CRADA with GILD), twelve patients with metastatic HPV-16+ carcinomas were treated. They had 3-7 prior therapies, eight refractory to an anti-PD-1. It was safe ((S)AEs due to LD chemo and high-dose IL-2) and there were six objective responses across all three dose levels tested (likely due to the high levels given).

Personally, I hope TCRX test in a similar patient population. Based on the additional transgenes, should lead to an improved depth and duration of response (assuming dose levels in the same range).

However, none of the responses are ongoing (from memory, the longest was ~14 months). This due to a number of cancer cell intrinsic factors, mostly related to antigen processing and presentation, as well as T-cell recognition and killing.